Harbor Capital Advisors’s Gilead Sciences GILD Stock Holding History

Harbor Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127K	Sell	911 -374	-29%	-$52.4K	0.01%	621
2025 Q4	$158K	Sell	1,285 -88	-6%	-$10.7K	0.01%	647
2025 Q3	$152K	Buy	1,373 +751	+121%	+$85.4K	0.01%	627
2025 Q2	$69K	Buy	622 +174	+39%	+$18.5K	﹤0.01%	673
2025 Q1	$50K	Sell	448 -27,173	-98%	-$2.8M	﹤0.01%	709
2024 Q4	$2.55M	Buy	27,621 +616	+2%	+$55.5K	0.11%	238
2024 Q3	$2.26M	Buy	27,005 +695	+3%	+$53K	0.1%	280
2024 Q2	$1.8M	Buy	26,310 +48	+0.2%	+$3.2K	0.14%	225
2024 Q1	$1.92M	Buy	+26,262	New	+$2.02M	0.25%	87

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Harbor Capital Advisors's GILD Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Gilead Sciences (GILD) stake by 29% in Q1 2026, selling an estimated $52.4K and leaving 911 shares worth $127K. The position accounts for 0.01% of the portfolio, ranked #621.

Harbor Capital Advisors first reported a position in GILD in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.55M in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Harbor Capital Advisors held 911 shares of Gilead Sciences worth $127K as of Q1 2026.
Harbor Capital Advisors sold 374 Gilead Sciences shares in Q1 2026, an estimated $52.4K.
Gilead Sciences made up 0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #621 holding.
Harbor Capital Advisors first reported a position in Gilead Sciences in Q1 2024 and has held it in 9 quarters since.
Harbor Capital Advisors's Gilead Sciences position peaked at $2.55M in Q4 2024.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.